Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model.

Montero M, VanScoy BD, López-Causapé C, Conde H, Adams J, Segura C, Zamorano L, Oliver A, Horcajada JP, Ambrose PG.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00026-18. doi: 10.1128/AAC.00026-18. Print 2018 May.

2.

Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal Activity.

Ambrose PG, VanScoy BD, Adams J, Fikes S, Bader JC, Bhavnani SM, Rubino CM.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02257-17. doi: 10.1128/AAC.02257-17. Print 2018 Apr.

3.

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.

Zhao M, Lepak AJ, VanScoy B, Bader JC, Marchillo K, Vanhecker J, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02542-17. doi: 10.1128/AAC.02542-17. Print 2018 Apr.

4.

Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.

Lepak AJ, Zhao M, VanScoy B, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02154-17. doi: 10.1128/AAC.02154-17. Print 2018 Feb.

5.

β-Lactamase inhibitors: what you really need to know.

Ambrose PG, Lomovskaya O, Griffith DC, Dudley MN, VanScoy B.

Curr Opin Pharmacol. 2017 Oct;36:86-93. doi: 10.1016/j.coph.2017.09.001. Epub 2017 Oct 27. Review.

PMID:
29096172
6.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model.

VanScoy BD, Tenero D, Turner S, Livermore DM, McCauley J, Conde H, Bhavnani SM, Rubino CM, Ambrose PG.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01052-17. doi: 10.1128/AAC.01052-17. Print 2017 Dec.

7.

Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.

Ambrose PG, VanScoy BD, Trang M, McCauley-Miller J, Conde H, Bhavnani SM, Alexander DC, Friedrich LV.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00630-17. doi: 10.1128/AAC.00630-17. Print 2017 Dec.

8.

In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00476-17. doi: 10.1128/AAC.00476-17. Print 2017 Jun.

9.

Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against Itself.

Ambrose PG, VanScoy B, Conde H, McCauley J, Rubino CM, Bhavnani SM.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01605-16. doi: 10.1128/AAC.01605-16. Print 2017 Jan.

10.

Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model.

VanScoy B, McCauley J, Bhavnani SM, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5141-5. doi: 10.1128/AAC.00355-16. Print 2016 Sep.

11.

Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model.

VanScoy BD, Trang M, McCauley J, Conde H, Bhavnani SM, Friedrich LV, Alexander DC, Ambrose PG.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3891-6. doi: 10.1128/AAC.02943-15. Print 2016 Jul.

12.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.

Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2075-80. doi: 10.1128/AAC.02747-15. Print 2016 Apr.

13.

Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.

VanScoy BD, McCauley J, Ellis-Grosse EJ, Okusanya OO, Bhavnani SM, Forrest A, Ambrose PG.

Antimicrob Agents Chemother. 2015 Dec;59(12):7170-7. doi: 10.1128/AAC.04955-14. Epub 2015 Jun 22.

14.

Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.

VanScoy BD, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2014 Oct;58(10):6024-31. doi: 10.1128/AAC.02310-13. Epub 2014 Jul 28.

15.

Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.

Vanscoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2013 Dec;57(12):5924-30. doi: 10.1128/AAC.00656-13. Epub 2013 Sep 16.

16.

Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children.

Louie A, Vanscoy B, Liu W, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2013 Dec;57(12):5946-60. doi: 10.1128/AAC.02616-12. Epub 2013 Sep 16.

17.

Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.

Vanscoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, Jones RN, Okusanya OO, Friedrich LV, Steenbergen J, Ambrose PG.

Antimicrob Agents Chemother. 2013 Sep;57(9):4134-8. doi: 10.1128/AAC.00461-13. Epub 2013 Jun 17.

18.

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.

VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2013 Jun;57(6):2809-14. doi: 10.1128/AAC.02513-12. Epub 2013 Apr 29.

19.

Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.

Louie A, VanScoy BD, Brown DL, Kulawy RW, Heine HS, Drusano GL.

Antimicrob Agents Chemother. 2012 Mar;56(3):1229-39. doi: 10.1128/AAC.01109-10. Epub 2011 Dec 12.

20.

Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.

Louie A, Vanscoy BD, Heine HS 3rd, Liu W, Abshire T, Holman K, Kulawy R, Brown DL, Drusano GL.

Antimicrob Agents Chemother. 2012 Jan;56(1):513-7. doi: 10.1128/AAC.05724-11. Epub 2011 Nov 7.

21.

Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases.

Louie A, Castanheira M, Liu W, Grasso C, Jones RN, Williams G, Critchley I, Thye D, Brown D, Vanscoy B, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2012 Jan;56(1):258-70. doi: 10.1128/AAC.05005-11. Epub 2011 Oct 24.

22.

Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.

Drusano GL, Bonomo RA, Bahniuk N, Bulitta JB, Vanscoy B, Defiglio H, Fikes S, Brown D, Drawz SM, Kulawy R, Louie A.

Antimicrob Agents Chemother. 2012 Jan;56(1):231-42. doi: 10.1128/AAC.05252-11. Epub 2011 Oct 17.

23.

Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets.

Drusano GL, Lodise TP, Melnick D, Liu W, Oliver A, Mena A, VanScoy B, Louie A.

Antimicrob Agents Chemother. 2011 Jul;55(7):3406-12. doi: 10.1128/AAC.01559-10. Epub 2011 May 16.

24.

Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.

Louie A, Stein DS, Zack JZ, Liu W, Conde H, Fregeau C, Vanscoy BD, Drusano GL.

Antimicrob Agents Chemother. 2011 Jul;55(7):3295-304. doi: 10.1128/AAC.01324-10. Epub 2011 Apr 18.

25.

Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.

Louie A, Vanscoy B, Liu W, Kulawy R, Brown D, Heine HS, Drusano GL.

Antimicrob Agents Chemother. 2011 Jun;55(6):2623-8. doi: 10.1128/AAC.01374-10. Epub 2011 Apr 12.

26.

Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia.

Drusano GL, Vanscoy B, Liu W, Fikes S, Brown D, Louie A.

Antimicrob Agents Chemother. 2011 Jun;55(6):2693-5. doi: 10.1128/AAC.01687-10. Epub 2011 Mar 21.

27.

Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.

Louie A, Heine HS, VanScoy B, Eichas A, Files K, Fikes S, Brown DL, Liu W, Kinzig-Schippers M, Sörgel F, Drusano GL.

Antimicrob Agents Chemother. 2011 Feb;55(2):822-30. doi: 10.1128/AAC.00818-10. Epub 2010 Nov 29.

28.

Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.

Louie A, Heine HS, Kim K, Brown DL, VanScoy B, Liu W, Kinzig-Schippers M, Sörgel F, Drusano GL.

Antimicrob Agents Chemother. 2008 Jul;52(7):2486-96. doi: 10.1128/AAC.01439-07. Epub 2008 May 5.

29.

The use of streptolysin o for the treatment of scars, adhesions and fibrosis: initial investigations using murine models of scleroderma.

Mamber SW, Long V, Rhodes RG, Pond-Tor S, Wheeler LR, Fredericks K, Vanscoy B, Sauniere JF, Steinschneider R, Laurent JC, McMichael J.

Nonlinearity Biol Toxicol Med. 2004 Apr;2(2):67-87. doi: 10.1080/15401420490464295.

Supplemental Content

Loading ...
Support Center